GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » Net Margin %

TheraCryf (LSE:TCF) Net Margin % : -368.43% (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is TheraCryf Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. TheraCryf's Net Income for the six months ended in Sep. 2023 was £-1.46 Mil. TheraCryf's Revenue for the six months ended in Sep. 2023 was £0.40 Mil. Therefore, TheraCryf's net margin for the quarter that ended in Sep. 2023 was -368.43%.

The historical rank and industry rank for TheraCryf's Net Margin % or its related term are showing as below:

LSE:TCF' s Net Margin % Range Over the Past 10 Years
Min: -1378.35   Med: -1146.53   Max: -400.12
Current: -400.12


LSE:TCF's Net Margin % is ranked worse than
61.47% of 1033 companies
in the Biotechnology industry
Industry Median: -162.58 vs LSE:TCF: -400.12

TheraCryf Net Margin % Historical Data

The historical data trend for TheraCryf's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Net Margin % Chart

TheraCryf Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1,378.35 - -914.71

TheraCryf Semi-Annual Data
Mar13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -428.51 -368.43

Competitive Comparison of TheraCryf's Net Margin %

For the Biotechnology subindustry, TheraCryf's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TheraCryf's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TheraCryf's Net Margin % distribution charts can be found below:

* The bar in red indicates where TheraCryf's Net Margin % falls into.



TheraCryf Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

TheraCryf's Net Margin for the fiscal year that ended in Mar. 2023 is calculated as

Net Margin=Net Income (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-4.043/0.442
=-914.71 %

TheraCryf's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-1.459/0.396
=-368.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TheraCryf  (LSE:TCF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


TheraCryf Net Margin % Related Terms

Thank you for viewing the detailed overview of TheraCryf's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf (LSE:TCF) Business Description

Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (LSE:TCF) Headlines

From GuruFocus

Tcf Financial Corp (TCF) EVP, CFO Brian W Maass Sold $887,338 of Shares

By GuruFocus Research GuruFocus Editor 02-05-2021

Lindsay Yousif Named TCF Bank's Chief Compliance Officer

By Business Wire Business Wire 11-19-2020

Tcf Financial Corp (TCF) EVP, CFO Brian W Maass Sold $500,259 of Shares

By GuruFocus Research GuruFocus Editor 02-23-2021

TCF Financial Corp. CEO Craig R. Dahl to Retire

By Business Wire Business Wire 10-27-2020